Literature DB >> 8370421

IFN-gamma and TNF-alpha secretion by CD4+ and CD8+ TCR alpha beta + T-cell clones derived early after allogeneic bone marrow transplantation.

O Bruserud1, W Hamann, S Patel, G Ehninger, H Schmidt, G Pawelec.   

Abstract

Secretion of the potentially antileukaemic cytokines IFN-gamma and TNF-alpha was investigated for CD4+ and CD8+ TCR alpha beta + T-cell clones derived from 4 leukaemia patients 3-6 weeks after allogeneic BMT. We investigated cytokine secretion in response to the activation signal accessory cells+phytohaemagglutinin+Interleukin 2. All clones derived after BMT were capable of IFN-gamma and TNF-alpha secretion, and both for CD4+ (n = 96) and CD8+ (n = 8) T cells quantities of IFN-gamma and TNF-alpha were significantly correlated with one another. When comparing the overall results for posttransplant and normal T-cell clones derived from 2 bone marrow donors (n = 65), both CD4+ and CD8+ TCR alpha beta + T-cell clones showed increased IFN-gamma production, and CD4+ but not CD8+ clones showed a decreased TNF-alpha secretion. The results suggest that noncytotoxic T cells derived after allogeneic BMT can produce IFN-gamma and TNF-alpha and may thus be capable of mediating antileukaemic effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370421     DOI: 10.1111/j.1600-0609.1993.tb01596.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

Review 1.  The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.

Authors:  Håkon Reikvam; Hanne Fredly; Astrid Olsnes Kittang; Oystein Bruserud
Journal:  Toxins (Basel)       Date:  2013-02-18       Impact factor: 4.546

Review 2.  Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.

Authors:  Tor Henrik Anderson Tvedt; Elisabeth Ersvaer; Anders Aune Tveita; Øystein Bruserud
Journal:  Front Immunol       Date:  2017-06-08       Impact factor: 7.561

3.  A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.

Authors:  Eric J Hsu; Xuezhi Cao; Benjamin Moon; Joonbeom Bae; Zhichen Sun; Zhida Liu; Yang-Xin Fu
Journal:  Nat Commun       Date:  2021-05-13       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.